Eledon Pharmaceuticals' CSO to Discuss Pipeline at Guggenheim Biotech Summit
Event summary
- Eledon Pharmaceuticals' CSO Steven Perrin to participate in fireside chat at Guggenheim Biotech Summit on February 12, 2026.
- Event scheduled for 10:00 a.m. ET (7:00 a.m. PT).
- Company developing tegoprubart, an anti-CD40L antibody for immune-modulating therapies.
- Key focus areas include kidney allograft transplantation, xenotransplantation, islet cell transplantation, and ALS.
The big picture
Eledon Pharmaceuticals' participation in the Guggenheim Biotech Summit highlights its focus on advancing tegoprubart through clinical development. The event provides a platform to discuss the company's strategic positioning in the immune-modulating therapies market, particularly in areas like transplantation and ALS. Investors will be watching for updates on clinical trial progress and potential partnerships.
What we're watching
- Pipeline Progress
- How Eledon's presentation will impact investor perception of its clinical-stage pipeline.
- Strategic Positioning
- Whether Eledon can differentiate tegoprubart in competitive immune-modulating therapies market.
- Market Dynamics
- The pace at which Eledon advances its lead product through clinical trials.
Related topics